GlassScriptPhysician profile
Mary M Albritton
NPI 1275744112
$10,743.28
in general payments reported to CMS, 2019-2025
49 companies · $1,700 in 2025
The $1,700 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,208 · 2020: $1,499 · 2021: $1,816 · 2022: $1,254 · 2023: $1,176 · 2024: $1,090 · 2025: $1,700.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,942 · Education: $24.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,941.72 |
| Education | $24.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,693.15 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $886.12 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Corcept Therapeutics | $854.40 | 2019-2025 | Korlym |
| Amgen INC. | $611.34 | 2019-2025 | Tepezza, Evenity, Prolia |
| Amarin Pharma, INC. | $511.44 | 2019-2022 | |
| Abbvie INC. | $478.60 | 2019-2025 | Synthroid |
| Medtronic, INC. | $460.73 | 2021-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Sanofi-Aventis U.S. LLC | $420.65 | 2019-2025 | |
| Abbott Laboratories | $415.23 | 2019-2025 | Freestyle Libre 3 |
| Xeris Pharmaceuticals, INC. | $304.67 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Astrazeneca Pharmaceuticals LP | $287.27 | 2019-2021 | |
| Dexcom, INC. | $281.49 | 2019-2025 | Dexcom G6 Transmitter |
| Antares Pharma, INC. | $231.50 | 2019-2024 | Xyosted |
| Melinta Therapeutics, LLC | $210.97 | 2024-2025 | Kimyrsa, Orbactiv, Rezzayo |
| Currax Pharmaceuticals LLC | $199.14 | 2019-2023 | Contrave |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Albritton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.